Titre : Autoanticorps

Autoanticorps : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cellular Reprogramming
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Autoanticorps : Questions médicales les plus fréquentes", "headline": "Autoanticorps : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Autoanticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-22", "dateModified": "2025-02-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Autoanticorps" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Anticorps", "url": "https://questionsmedicales.fr/mesh/D000906", "about": { "@type": "MedicalCondition", "name": "Anticorps", "code": { "@type": "MedicalCode", "code": "D000906", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-protéines citrullinées", "alternateName": "Anti-Citrullinated Protein Antibodies", "url": "https://questionsmedicales.fr/mesh/D000075422", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-protéines citrullinées", "code": { "@type": "MedicalCode", "code": "D000075422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.095" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antinucléaires", "alternateName": "Antibodies, Antinuclear", "url": "https://questionsmedicales.fr/mesh/D000974", "about": { "@type": "MedicalCondition", "name": "Anticorps antinucléaires", "code": { "@type": "MedicalCode", "code": "D000974", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.204" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiphospholipides", "alternateName": "Antibodies, Antiphospholipid", "url": "https://questionsmedicales.fr/mesh/D017152", "about": { "@type": "MedicalCondition", "name": "Anticorps antiphospholipides", "code": { "@type": "MedicalCode", "code": "D017152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anticardiolipines", "alternateName": "Antibodies, Anticardiolipin", "url": "https://questionsmedicales.fr/mesh/D017153", "about": { "@type": "MedicalCondition", "name": "Anticorps anticardiolipines", "code": { "@type": "MedicalCode", "code": "D017153", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210.100" } } } ] }, { "@type": "MedicalWebPage", "name": "Facteur néphritique C3", "alternateName": "Complement C3 Nephritic Factor", "url": "https://questionsmedicales.fr/mesh/D003178", "about": { "@type": "MedicalCondition", "name": "Facteur néphritique C3", "code": { "@type": "MedicalCode", "code": "D003178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.300" } } }, { "@type": "MedicalWebPage", "name": "Immunoconglutinines", "alternateName": "Immunoconglutinins", "url": "https://questionsmedicales.fr/mesh/D037561", "about": { "@type": "MedicalCondition", "name": "Immunoconglutinines", "code": { "@type": "MedicalCode", "code": "D037561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.390" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobulines thyréostimulantes", "alternateName": "Immunoglobulins, Thyroid-Stimulating", "url": "https://questionsmedicales.fr/mesh/D018828", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines thyréostimulantes", "code": { "@type": "MedicalCode", "code": "D018828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.480" } } }, { "@type": "MedicalWebPage", "name": "Facteur rhumatoïde", "alternateName": "Rheumatoid Factor", "url": "https://questionsmedicales.fr/mesh/D012217", "about": { "@type": "MedicalCondition", "name": "Facteur rhumatoïde", "code": { "@type": "MedicalCode", "code": "D012217", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.732" } } } ], "about": { "@type": "MedicalCondition", "name": "Autoanticorps", "alternateName": "Autoantibodies", "code": { "@type": "MedicalCode", "code": "D001323", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Iago Pinal-Fernandez", "url": "https://questionsmedicales.fr/author/Iago%20Pinal-Fernandez", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov." } }, { "@type": "Person", "name": "Katherine Pak", "url": "https://questionsmedicales.fr/author/Katherine%20Pak", "affiliation": { "@type": "Organization", "name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA." } }, { "@type": "Person", "name": "Sarah L Tansley", "url": "https://questionsmedicales.fr/author/Sarah%20L%20Tansley", "affiliation": { "@type": "Organization", "name": "Department of Pharmacy and pharmacology, University of Bath, Bath, UK." } }, { "@type": "Person", "name": "Gunnar Houen", "url": "https://questionsmedicales.fr/author/Gunnar%20Houen", "affiliation": { "@type": "Organization", "name": "Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark. gh@ssi.dk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.", "datePublished": "2023-03-21", "url": "https://questionsmedicales.fr/article/36941149", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jcyt.2023.02.007" } }, { "@type": "ScholarlyArticle", "name": "Riceberry Rice Germination and UVB Radiation Enhance Protocatechuic Acid and Vanillic Acid to Reduce Cellular Oxidative Stress and Suppress B16F10 Melanogenesis Relating to F-Actin Rearrangement.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36771569", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/plants12030484" } }, { "@type": "ScholarlyArticle", "name": "Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome.", "datePublished": "2022-11-03", "url": "https://questionsmedicales.fr/article/36405594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fmed.2022.1042501" } }, { "@type": "ScholarlyArticle", "name": "Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France.", "datePublished": "2022-10-26", "url": "https://questionsmedicales.fr/article/36388890", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fmed.2022.1027708" } }, { "@type": "ScholarlyArticle", "name": "Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).", "datePublished": "2022-08-30", "url": "https://questionsmedicales.fr/article/36248617", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jha2.544" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" }, { "@type": "ListItem", "position": 8, "name": "Autoanticorps", "item": "https://questionsmedicales.fr/mesh/D001323" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Autoanticorps - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Autoanticorps", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Autoanticorps", "description": "Comment détecte-t-on les autoanticorps ?\nQuels tests sont utilisés pour les autoanticorps ?\nLes autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?\nPeut-on avoir des autoanticorps sans symptômes ?\nQuel rôle jouent les autoanticorps dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Autoanticorps", "description": "Quels symptômes sont associés aux autoanticorps ?\nLes autoanticorps causent-ils des douleurs articulaires ?\nPeut-on avoir des symptômes neurologiques avec des autoanticorps ?\nLes éruptions cutanées sont-elles liées aux autoanticorps ?\nLes autoanticorps peuvent-ils affecter les organes internes ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Autoanticorps", "description": "Peut-on prévenir la production d'autoanticorps ?\nLes vaccinations influencent-elles les autoanticorps ?\nLe stress peut-il augmenter les autoanticorps ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes examens médicaux réguliers aident-ils à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Autoanticorps", "description": "Comment traite-t-on les maladies liées aux autoanticorps ?\nLes traitements sont-ils les mêmes pour tous les autoanticorps ?\nLes thérapies biologiques sont-elles efficaces contre les autoanticorps ?\nPeut-on guérir des maladies causées par des autoanticorps ?\nLes changements de mode de vie aident-ils à gérer les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Autoanticorps", "description": "Quelles complications peuvent survenir avec des autoanticorps ?\nLes autoanticorps peuvent-ils causer des maladies cardiovasculaires ?\nLes complications sont-elles réversibles ?\nLes infections sont-elles plus fréquentes avec des autoanticorps ?\nLes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Autoanticorps", "description": "Quels sont les facteurs de risque pour les autoanticorps ?\nL'âge influence-t-il la production d'autoanticorps ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLes déséquilibres hormonaux affectent-ils les autoanticorps ?", "url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Cellular+Reprogramming&page=999#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les autoanticorps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les autoanticorps sont détectés par des tests sanguins spécifiques, comme l'ELISA." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les autoanticorps ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests courants incluent le dosage des anticorps antinucléaires (ANA) et des anticorps spécifiques." } }, { "@type": "Question", "name": "Les autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur présence peut varier selon la maladie et le stade de la maladie." } }, { "@type": "Question", "name": "Peut-on avoir des autoanticorps sans symptômes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des autoanticorps sans présenter de symptômes cliniques." } }, { "@type": "Question", "name": "Quel rôle jouent les autoanticorps dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils aident à confirmer le diagnostic de maladies auto-immunes et à évaluer leur activité." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux autoanticorps ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais peuvent inclure fatigue, douleurs articulaires et éruptions cutanées." } }, { "@type": "Question", "name": "Les autoanticorps causent-ils des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des douleurs articulaires dans des maladies comme la polyarthrite rhumatoïde." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes neurologiques avec des autoanticorps ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Les éruptions cutanées sont-elles liées aux autoanticorps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées peuvent survenir dans des maladies comme le lupus érythémateux systémique." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils affecter les organes internes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent endommager des organes comme les reins, le cœur ou les poumons dans certaines maladies." } }, { "@type": "Question", "name": "Peut-on prévenir la production d'autoanticorps ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode garantie, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles les autoanticorps ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent déclencher des autoanticorps, mais les bénéfices l'emportent souvent." } }, { "@type": "Question", "name": "Le stress peut-il augmenter les autoanticorps ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les maladies auto-immunes et augmenter les autoanticorps." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants et en oméga-3 peut aider à réduire l'inflammation." } }, { "@type": "Question", "name": "Les examens médicaux réguliers aident-ils à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent aider à détecter précocement les maladies auto-immunes." } }, { "@type": "Question", "name": "Comment traite-t-on les maladies liées aux autoanticorps ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des immunosuppresseurs, des anti-inflammatoires et des corticostéroïdes." } }, { "@type": "Question", "name": "Les traitements sont-ils les mêmes pour tous les autoanticorps ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, le traitement dépend du type de maladie auto-immune et des autoanticorps présents." } }, { "@type": "Question", "name": "Les thérapies biologiques sont-elles efficaces contre les autoanticorps ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines thérapies biologiques ciblent spécifiquement les mécanismes des maladies auto-immunes." } }, { "@type": "Question", "name": "Peut-on guérir des maladies causées par des autoanticorps ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de guérison, mais les traitements peuvent contrôler les symptômes et la progression." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils à gérer les autoanticorps ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée, l'exercice et la gestion du stress peuvent aider à la gestion." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des autoanticorps ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages aux organes, des infections et des troubles auto-immuns." } }, { "@type": "Question", "name": "Les autoanticorps peuvent-ils causer des maladies cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains autoanticorps sont associés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent causer des dommages permanents." } }, { "@type": "Question", "name": "Les infections sont-elles plus fréquentes avec des autoanticorps ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies auto-immunes ont un risque accru d'infections." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, comme des troubles cognitifs ou des crises." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les autoanticorps ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, le sexe féminin et certaines infections." } }, { "@type": "Question", "name": "L'âge influence-t-il la production d'autoanticorps ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la production d'autoanticorps augmente souvent avec l'âge, surtout chez les femmes." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou à des infections peut déclencher la production d'autoanticorps." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de maladies auto-immunes et d'autoanticorps." } }, { "@type": "Question", "name": "Les déséquilibres hormonaux affectent-ils les autoanticorps ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les déséquilibres hormonaux, notamment chez les femmes, peuvent influencer la production d'autoanticorps." } } ] } ] }

Sources (10000 au total)

International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.

Allogeneic hematopoietic stem cell transplant is a curative approach for many malignant and non-malignant hematologic conditions. Despite advances in its prevention and treatment, the morbidity and mo... We conducted a search for scientific literature in PubMed® and ongoing clinical trials in clinicaltrial.gov with the keywords "Graft-versus-Host Disease (GVHD)," "Cellular Therapies," "Regulatory T ce... Although most of the existing clinical data focus on cellular therapies for GVHD prevention, there are observational and interventional clinical studies that explore the potential for cellular therapi... There are many ongoing clinical trials to date with the promise to expand our actual knowledge on the role of cellular therapies for GVHD treatment in an attempt to improve GVHD-related outcomes in th...

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome.

Neutropenia and cytokine release syndrome (CRS) are two major toxicities of chimeric antigen receptor (CAR)-T cell therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an ideal candid... Nine patients received GM-CSF therapy who displayed moderate neutropenia with absolute neutrophil counts (ANC) < 1,500 cells/mm... The median duration of GM-CSF intervention was 15 days (4-30). CAR T-cell expansion was observed in peripheral blood (PB) of seven patients (7/9). The median baseline and peak CAR T cells count in PB ... This study provides evidence for the clinical feasibility of combining CAR T-cell therapy with the GM-CSF to treat neutropenia patients with concomitant declination of circulating CAR T-cell....

Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France.

Heart transplant (HT) recipients have a high risk of developing severe COVID-19. Immunoglobulin G antibodies are considered to provide protective immunity and T-cell activity is thought to confer prot... In 96 HT patients, a IFN-γ release assay and an anti-Spike antibody test were used to evaluate the ability of SARS-CoV-2 mRNA vaccines to generate cellular and humoral immune response. Blood samples w... Three to five months after vaccination, three doses of vaccine induced a positive SARS-CoV-2 T-cell response in 47% of recipients and a positive humoral response in 83% of recipients, 11.1% of patient... Our study revealed that T and B immunity decreases over time, leading us to suggest the interest of a booster vaccination at 5 months after the third dose. Moreover, a close follow-up of immune respon...

High-throughput single cell metabolomics and cellular heterogeneity exploration by inertial microfluidics coupled with pulsed electric field-induced electrospray ionization-high resolution mass spectrometry.

Single cell metabolomics can obtain the metabolic profiles of individual cells and reveal cellular heterogeneity. However, high-throughput single-cell mass spectrometry (MS) analysis under physiologic...

Impact on Inpatient Length of Stay in Adults with Deep Partial-Thickness Burns: Comparing the Bioengineered Allogeneic Cellularized Construct Expanded-Access Trial with National Burn Repository Data.

To investigate the effect of StrataGraft (bioengineered allogeneic cellularized construct [BACC]) treatment on inpatient length of stay (LOS) as an indicator of hospital resource utilization.... Data from the single-arm StrataCAT trial for adult patients with deep partial-thickness (DPT) burns who received BACC were compared with data from a matched external control arm comprising patients wh... The BACC and NBR Autograft cohorts included 47 and 2641 patients, respectively. Following matching, the Autograft cohort had 137 patients and was weighted to 47 patients. Patients in the BACC and fina... The significantly reduced inpatient LOS observed with BACC compared to Autograft in adults with DPT burns may translate into reduced burden on the healthcare system, reduced costs for inpatient burn t...

Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.

This study examines the humoral and cellular response in multiple sclerosis (MS) patients on anti-CD20 therapy before and after the 1st to 4th BNT162b2 mRNA SARS-CoV-2 vaccination and the relationship... Participants with McDonald 2017 MS that were treated with ocrelizumab were included. The study duration was throughout the COVID-19 pandemic until four months after fourth mRNA SARS-CoV-2 vaccination ... The rate of anti-RBD positive participants increased substantially between the third and fourth vaccination from 22.2% to 55.9% (median 54.7 BAU/mL; IQR: 14.5 - 221.2 BAU/mL and 607.7 BAU/mL; IQR: 29.... Low levels or absence of specific anti-RBD following vaccination, with a significant increase after breakthrough infections and boosted by the fourth vaccination. T-cell reactivity remained sustained ...